Literature DB >> 20084037

Can serum cystatin C reflect the glomerular filtration rate accurately in pediatric patients under chemotherapeutic treatment? A comparative study with Tc-99m DTPA two-plasma sample method.

Funda Aydin1, Gülsün Tezcan, Ozgül Güngör, Arzu Kin Cengiz, Volkan Hazar, Sema Akman, Ayfer Gür Güven, Akif Yeşilipek, Halide Akbaş, Firat Güngör.   

Abstract

OBJECTIVE: It was assessed whether cystatin C (cysC) could be used as a marker of glomerular filtration rate (GFR) by considering the technetium-99m diethylenetriamine penta-acetate (Tc-99m DTPA)-two blood sample method (GFRTc-99m DTPA) as the reference in pediatric patients under chemotherapeutic treatment.
METHODS: The chemotherapy group (CG) consisted of 31 patients (21 females, 10 males median age: 8.2 years; range: 2-16 years) who had been planned to receive allogenic hematopoietic stem cell transplantation. All patients in the CG received conditioning regimen (includes chemotherapy protocol) before hematopoietic stem cell transplantation. In addition, 21 patients (14 females, seven males median age: 9.5 years; range: 4-16 years) without any chemotherapy (nonchemotherapy group: nCG) were also prospectively investigated. Serum cysC, serum creatinine, GFRTc-99m DTPA, and GFR with a cysC-based formula (GFRcysC) were analyzed. Tubular function was also assessed.
RESULTS: Although we found good correlation between GFRTc-99m DTPA and cysC (r = -0.78), GFRTc-99m DTPA and GFRcysC (r = 0.91), cysC and creatinine (r = 0.91) in nCG, the same correlations were poor in CG (r = -0.42, r = 0.43, r = 0.46, respectively). Tubular function was impaired after chemotherapy. Bias+/-1.96 SD values were -6+/-15.7 and -3+/-54.8 ml/min/1.73 m in nCG and CG, respectively. Precision was also better in nCG (10 ml/min/1.73 m) than in CG (27.6 ml/min/1.73 m).
CONCLUSION: Serum cysC and GFRcysC cannot reflect GFR accurately in pediatric patients under chemotherapeutic treatment. Tubular cell damage induced by chemotherapeutics could be a responsible factor through the impairment of tubular absorption and metabolism of cysC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20084037     DOI: 10.1097/MNM.0b013e328334fc6f

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  4 in total

1.  Accuracy of cystatin C for the detection of abnormal renal function in children undergoing chemotherapy for malignancy: a systematic review using individual patient data.

Authors:  Penny Whiting; Kate Birnie; Jonathan A C Sterne; Catherine Jameson; Rod Skinner; Bob Phillips
Journal:  Support Care Cancer       Date:  2017-12-06       Impact factor: 3.603

Review 2.  Acute kidney injury in pediatric hematopoietic cell transplantation: critical appraisal and consensus.

Authors:  Rupesh Raina; Rolla Abu-Arja; Sidharth Sethi; Richa Dua; Ronith Chakraborty; James T Dibb; Rajit K Basu; John Bissler; Melvin Bonilla Felix; Patrick Brophy; Timothy Bunchman; Khalid Alhasan; Dieter Haffner; Yap Hui Kim; Christopher Licht; Mignon McCulloch; Shina Menon; Ali Mirza Onder; Prajit Khooblall; Amrit Khooblall; Veronika Polishchuk; Hemalatha Rangarajan; Azmeri Sultana; Clifford Kashtan
Journal:  Pediatr Nephrol       Date:  2022-02-28       Impact factor: 3.651

3.  Estimated versus measured glomerular filtration rate in children before hematopoietic cell transplantation.

Authors:  Benjamin L Laskin; Edward Nehus; Jens Goebel; Susan Furth; Stella M Davies; Sonata Jodele
Journal:  Biol Blood Marrow Transplant       Date:  2014-07-17       Impact factor: 5.742

4.  CamGFR v2: A New Model for Estimating the Glomerular Filtration Rate from Standardized or Non-standardized Creatinine in Patients with Cancer.

Authors:  Edward H Williams; Thomas R Flint; Claire M Connell; Daniel Giglio; Hassal Lee; Taehoon Ha; Eva Gablenz; Nicholas J Bird; James M J Weaver; Harry Potts; Cameron T Whitley; Michael A Bookman; Andy G Lynch; Hannah V Meyer; Simon Tavaré; Tobias Janowitz
Journal:  Clin Cancer Res       Date:  2020-12-10       Impact factor: 13.801

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.